---
figid: PMC6218675__fphys-09-01533-g0002
figlink: /pmc/articles/PMC6218675/figure/F2/
number: F2
caption: Summary of the potential treatments tested so far in EDMD. Schematic drawing
  representing several treatment strategies that have been developed for EDMD. The
  portrayed treatments target diverse mechanisms occurring either in the cytoplasm,
  e.g., autophagy in the lysosomes, or in the nucleus, including exon-skipping or
  trans-splicing strategies. The treatment strategies addressed to EDMD have generally
  been developed to target MAPK signaling pathway or to induce autophagy and these
  include different inhibitors of components of these pathways such as selumetinib
  or temsirolimus. To target apoptosis, the utilization of shRNA specific to Fox O1
  and 3 has been developed. Others treatments and strategies such as the use of paclitaxel
  to stabilize microtubules or gene therapy to convert the mutant transcript into
  a normal transcript or remove an in-frame exon containing a mutation have been studied.
  AKT, protein kinase B; ASK1, apoptosis signal-regulating kinase 1; ASO, antisense
  oligonucleotide; ERK, extracellular signal-regulated kinase; FoxO, forkhead box
  O; MEK1/2, MAPK/ERK kinase 1/2; MEKK1/4, mitogen-activated protein kinase kinase
  kinase 1/4; MKK3/6, mitogen-activated protein kinase kinase 3/6; MLK3, mitogen-activated
  protein kinase kinase kinase 11; mTORC1, mammalian target of rapamycin complex 1;
  PI3K, Phosphoinositide 3-kinase; Raf, proto-oncogen serine/threonine-protein kinase;
  TAK1, mitogen-activated protein kinase kinase kinase 7.
pmcid: PMC6218675
papertitle: The Pathogenesis and Therapies of Striated Muscle Laminopathies.
reftext: Astrid Brull, et al. Front Physiol. 2018;9:1533.
pmc_ranked_result_index: '184859'
pathway_score: 0.9030644
filename: fphys-09-01533-g0002.jpg
figtitle: Summary of the potential treatments tested so far in EDMD
year: '2018'
organisms: Homo sapiens
ndex: c3c6435e-df11-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6218675__fphys-09-01533-g0002.html
  '@type': Dataset
  description: Summary of the potential treatments tested so far in EDMD. Schematic
    drawing representing several treatment strategies that have been developed for
    EDMD. The portrayed treatments target diverse mechanisms occurring either in the
    cytoplasm, e.g., autophagy in the lysosomes, or in the nucleus, including exon-skipping
    or trans-splicing strategies. The treatment strategies addressed to EDMD have
    generally been developed to target MAPK signaling pathway or to induce autophagy
    and these include different inhibitors of components of these pathways such as
    selumetinib or temsirolimus. To target apoptosis, the utilization of shRNA specific
    to Fox O1 and 3 has been developed. Others treatments and strategies such as the
    use of paclitaxel to stabilize microtubules or gene therapy to convert the mutant
    transcript into a normal transcript or remove an in-frame exon containing a mutation
    have been studied. AKT, protein kinase B; ASK1, apoptosis signal-regulating kinase
    1; ASO, antisense oligonucleotide; ERK, extracellular signal-regulated kinase;
    FoxO, forkhead box O; MEK1/2, MAPK/ERK kinase 1/2; MEKK1/4, mitogen-activated
    protein kinase kinase kinase 1/4; MKK3/6, mitogen-activated protein kinase kinase
    3/6; MLK3, mitogen-activated protein kinase kinase kinase 11; mTORC1, mammalian
    target of rapamycin complex 1; PI3K, Phosphoinositide 3-kinase; Raf, proto-oncogen
    serine/threonine-protein kinase; TAK1, mitogen-activated protein kinase kinase
    kinase 7.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NRAS
  - PIK3R4
  - MAP3K5
  - NR2C2
  - MAP3K11
  - MTOR
  - MAPK3
  - PIK3R5
  - HRAS
  - KRAS
  - RPTOR
  - MAPK13
  - MAPK8
  - MAPK11
  - AKT2
  - MAP2K1
  - PIK3CG
  - PIK3R3
  - ARAF
  - RAF1
  - BRAF
  - AKT3
  - AKT1
  - MAPK12
  - PIK3R6
  - MAPK9
  - MAPK10
  - MAPK1
  - FOXO6
  - FOXO1
  - FOXO3
  - FOXO4
  - MAPK14
  - PIK3CA
  - PIK3CB
  - MAP2K2
  - B3GAT1
  - PIK3CD
  - PDS8059
  - Selumetinib
  - ARRY-371797
  - Temsirolimus
  - AAG
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: ASK1
  symbol: ASK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP3K5
  entrez: '4217'
- word: TAK1
  symbol: TAK1
  source: hgnc_alias_symbol
  hgnc_symbol: NR2C2
  entrez: '7182'
- word: MLK3
  symbol: MLK3
  source: hgnc_prev_symbol
  hgnc_symbol: MAP3K11
  entrez: '4296'
- word: mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Erk1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: Erk1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: NK1/23
  symbol: NK-1
  source: hgnc_alias_symbol
  hgnc_symbol: B3GAT1
  entrez: '27087'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals:
- word: PDS8059
  source: MESH
  identifier: C001105
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: ARRY-371797
  source: MESH
  identifier: C000592910
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: AAG
  source: MESH
  identifier: C112765
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6218675__F2
redirect_from: /figures/PMC6218675__F2
figtype: Figure
---
